Qilu Hospital of Shandong University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1890-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.qiluhospital.com
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 48
- Registration Number
- NCT06541314
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Difficult Colonoscopy and Personality Traits
Not yet recruiting
- Conditions
- Colorectal Disorders
- Interventions
- Other: Fill in personality questionnaires
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 450
- Registration Number
- NCT06531226
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
Phase 2
Not yet recruiting
- Conditions
- The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 43
- Registration Number
- NCT06500247
- Locations
- 🇨🇳
Qilu hospital, Jinan, Shandong, China
Prediction of Mediastinal Station IV Lymph Node Metastasis in Non-small Cell Lung Cancer
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Diagnostic Test: Artificial Intelligence
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 150
- Registration Number
- NCT06496360
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 30
- Registration Number
- NCT06454578
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer
Not Applicable
Not yet recruiting
- Conditions
- Gastric Cancer
- Interventions
- Procedure: Preoperative injection of indocyanine green
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 484
- Registration Number
- NCT06421220
- Locations
- 🇨🇳
Qilu hospital of Shandong University, Jinan, Shandong, China
Circulating MrgD in Pulmonary Hypertension
Recruiting
- Conditions
- Pulmonary Hypertension
- Interventions
- Diagnostic Test: Western blot
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 90
- Registration Number
- NCT06365372
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
New Urethral Reconstruction in Robot-assisted Laparoscopic Radical Resection
Not Applicable
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Procedure: New urethral reconstruction
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 94
- Registration Number
- NCT06355076
- Locations
- 🇨🇳
Qilu hospital, Jinan, Shandong, China
Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin
Phase 4
Not yet recruiting
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 248
- Registration Number
- NCT06351891
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Effectiveness of Botulinum Toxin A in Preventing Scar Formation and Initial Exploration of "Optimal Concentration"
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 50
- Registration Number
- NCT06349733
- Locations
- 🇨🇳
Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, China